mitral valve disease; atrial dilatation; noncoding RNA; coronary artery bypass grafting THE PROGRESSION FROM HEALTHY to diseased myocardium involves complex changes in gene expression and subsequent changes in protein expression and activity. Some of these are protective, but others contribute to a worsening of the pathology. In recent years it has been shown that some of these pathological events involve posttranscriptional regulation by microRNAs (miRNA) (4, 33) . miRNAs are short noncoding RNA species of 20 -22 nucleotides in length that bind target sequences in the 3=-untranslated region of target genes to induce mRNA instability or to inhibit translation (10) . Each miRNA can influence multiple gene products, and conversely, each gene product is the target of multiple miRNAs (17) . Thus, changes in miRNA expression pattern have the potential to influence key cellular responses involved in cardiac pathology.
Atrial fibrillation (AF) is currently the most prevalent arrhythmia worldwide. The incidence of AF is increasing along with the aging of the population, increasing the prevalence of stroke and thromboembolic complications. AF contributes significantly to death and disability and is a major burden on the cost of health care. Chronic AF is a complication associated with the dilated atria of patients with valvular heart disease (VHD) or heart failure, and, in both of these diseases, AF worsens outcomes.
To gain insight into factors contributing to the development and perpetuation of AF, we performed genome-wide miRNA expression profiling using atrial appendage tissue from patients undergoing surgery for mitral valve disease (VHD) and those undergoing coronary artery bypass grafting (CABG). In addition, healthy left atrial (LA) appendage tissue was studied. The VHD group included patients with a history of chronic AF, defined as being present for Ͼ1 yr. We found that miRNA expression profiles showed differences between the different patient groups. We identified a number of miRNAs associated with VHD and miRNAs that differed in expression between the VHD patients with and without chronic AF. In addition, we demonstrated that LA and right atrium (RA) respond differently to the progression of VHD and the development of AF.
METHODS

Atrial tissue samples.
All of the studies were approved by the Human Ethics Committee of the Alfred Hospital, Melbourne, Australia, and all patients gave informed consent. Atrial appendage tissue was obtained from patients undergoing heart surgery at the Alfred Hospital, Melbourne. RA appendage was removed from patients undergoing mitral valve surgery (VHD patients) as well as those undergoing coronary artery bypass grafting (CABG patients). All CABG RA tissues used as control were from patients with normal left ventricular (LV) function. Left atrial appendage was removed from hearts of VHD patients with severely dilated LA. Healthy LA tissue was obtained from donor hearts not used for transplantation. VHD patients were classified as AF based on clinical assessment of chronic AF over at least 1 yr. Patients not showing AF over this period are classified as sinus rhythm (SR). In all cases, tissue removed at surgery was placed immediately in ice-cold saline. Our previous studies demonstrate that such tissues retain the ability to undergo responses to stimulation (35) . Surgically removed tissues were treated with RNAl-ater (Invitrogen) within 10 min of excision. RNAlater was removed after overnight treatment, and the samples were stored at Ϫ80°C.
Microarrays. Total RNA was extracted using TRIzol reagent (Ambion). miRNA hybridization was performed by the Ramaciotti Centre for Gene Function Analysis (Sydney, Australia) in three batches, onto Agilent G4470B (miRBase 10.1) and G4470C (miRBase 12.0) microarrays, which are glass slides containing eight arrays of ϳ15K hairpin probes, capable of recognizing a total of 966 mature miRNA sequences. Data have been deposited at http://www.ncbi. nlm.nih.gov/geo/, accession number GSE28954.
Microarray normalization, filtering, and batch removal. Because miRNA microarray data were generated in three batches, across six slides, and on two different array designs, we took care in the normalization and batch removal analysis of these data. Raw data from each array batch were normalized independently using robust multiarray average (15) , which utilizes the multiple probes per miRNA to obtain a robust estimate of the true expression level of each miRNAs, on the log 2 scale. Data from the three batches were combined and quantile normalized. Control probes (n ϭ 22) and miRNAs detected on none of the arrays (n ϭ 508) using the IsGeneDetected flag were filtered out, leaving 436 miRNAs. To remove any remaining batch effect, we fitted a linear model using limma (26) in the R/Bioconductor project (v2.11.1) (11), (8) :
where yi are the quantile normalized expression levels for miRNA i, is the intercept, and ␤1-␤6 represent the batch effect common to all arrays on each of the six array slides, and ε is the residual variation, which we subsequently used as the normalized, filtered, batch-batch removed expression data for each miRNA.
Differential expression. The correlation between technical replicates was estimated as 0.51 using the duplicate correlation method (27) and was used to more accurately assess the standard errors when fitting (Eq. 2) below.
To detect differentially expressed miRNAs, we fitted a treatment means parameterization linear model describing the seven different experimental groups:
where y i = are the normalized residuals from (Eq. 1), ε=i are the residual errors, and each term represents the average expression of miRNA i in each of the seven biological groups.
Detecting differential expression between groups is achieved by fitting contrasts to this linear model, for example:
Each contrast was compared with the null hypothesis of no differential expression via an empirical Bayes, moderated t-statistic, implemented in limma, in the R/Bioconductor project. The moderated t-statistic has been shown to be more appropriate than the Student's t-statistic for genomic data and is widely used in the analysis of whole genome microarrays (26) . Unadjusted P values produced for each miRNA VHD, valvular heart disease; LA and RA, left and right atria; CABG, coronary artery bypass grafting; SR, sinus rhythm; AF, atrial fibrillation. n, the number of samples used in the comparative analysis. Some of the LA and RA samples are from the same patient. LA volume was measured by echocardiography. Diabetes refers to a chronic history of diabetes for Ͼ 1 yr. There were no significant differences between the subgroups of VHD patients in terms of drug treatment. But the CABG groups different from the VHD group in that all CABG patients were using statins, whereas Ͻ40% of VHD patients were using statin therapy. Age and LA volume data are expressed as means Ϯ SE. under each contrast were independently adjusted for multiple testing by the false discovery rate (FDR) (1) . Differentially expressed miRNAs were those defined with an FDR Ͻ0.05 and fold change (FC) Ͼ1.5, up or down.
Heirarchical clustering. Heirarchical clustering images were generated upon the residuals from (Eq. 1), using GenePattern (v3.2.3, http://pwbc.garvan.unsw.edu.au/gp, Ref. 24 ), using Pearson correlation distance, and pairwise average-linkage clustering, with a rownormalized, relative color scheme.
Array validation by qRT-PCR. Total RNA was extracted from human atrial appendages by homogenizing 10 -20 mg of tissue using the TissueRuptor (QIAGEN) in 1 ml TRIzol reagent (Invitrogen) according to the manufacturer's instructions. miRNAs were measured using the TaqMan system (Applied Biosystems): miR-17 (ID 002308), miR-886-5p (ID 002193), miR-100 (ID 000437), miR-10b (ID 002218), miR-490-3p (ID 001037), miR-30c (ID 000419), miR-133b (ID 002247), miR-21 (ID 000397), miR-133a (ID 002246), and miR-146b-5p (ID 001097). Expression levels were calculated relative to the endogenous U6 control (ID 001973). Data from qRT-PCR showed a linear correlation with array data [correlation coefficient of 0.94, P Ͻ 0.001 and the power was 0.99 at 0.05 (Sigma Stat)]. Differences between groups were calculated by one-way ANOVA followed by Fisher's exact test (Sigma Stat). Where tissues were paired (same patient), a paired t-test was used. P Ͻ 0.05 was taken as significant. 
RESULTS
Patient groups studied. Chronic AF associated with mitral valve disease (VHD) was studied using RA and LA appendage tissues from VHD patients. CABG atrial samples, used in the study as control RA tissue, were all from patients with normal LV function. Healthy LA appendage tissue from unused transplant donor hearts was used as control for comparison with LA tissue from VHD patients. The tissue groups and the numbers of samples and the characteristics of the groups are shown in Table 1 . AF in VHD patients was defined based on a history of chronic AF for at least 1 yr prior to surgery. This subgroup was compared with samples from patients who remained in SR.
Validation of the miRNA array data. We sought to identify miRNAs potentially associated with AF in VHD patients by comparing miRNA expression profiles in LA and RA tissue from patients suffering chronic AF with those who remained in SR. The studies used a microarray system encompassing a total of 966 individual miRNA sequences, described under METHODS. Array data were validated using qRT-PCR measurements of 11 miRNAs with different signal strengths and different responses to disease status or different LA/RA expression profiles (2 were higher in RA tissue from patients with AF than in SR, and 4 were lower; whereas 1 was higher in VHD-LA than in VHD-RA, 2 were lower and 1 was unchanged). We found excellent correspondence between changes detected on the arrays and those found by direct qRT-PCR measurements ( Table 2 ). The exception was miR-17, which was 50% lower in expression VHD-LA compared with RA from the array data, but was unchanged when assayed by q-RT-PCR (Table 2 ). miRNAs that were differentially expressed between VHD-RA-SR and VHD-RA-AF were defined by FC Ͼ1.5, false discovery rate Ͻ0.05, P Ͻ 0.01. miRNAs described as 'up' are higher in VHD-RA-AF than in VHD-RA-SR, whereas 'down' means expression is higher in the SR group. miRNAs that were differentially expressed between VHD-LA and healthy-LA or CABG-RA and VHD-RA were defined by FC Ͼ1.5, false discovery rate Ͻ0.05, P Ͻ 0.01. miRNAs described as 'up' are higher in VHD-LA than in healthy-LA or in VHD-RA than in CABG-RA, whereas 'down' means expression is higher in the control group. miRNA expression patterns are influenced by AF status in RA tissue from VHD patients. Using array methodology, we examined miRNA expression patterns in RA tissue from VHD patients, with and without chronic AF [VHD-RA-AF (4 samples) and VHD-RA-SR (6 samples)]. We identified 47 differentially expressed miRNAs (FDR Ͻ 0.05, FC Ͼ 1.5). Of these, 15 were higher in the group with chronic AF and 32 showed lower expression compared with those who remained in SR (Fig. 1A,  Table 3 ). As noted above, findings were confirmed using qRT-PCR for three miRNAs whose expression was higher in the AF group and five miRNAs that showed lower expression in AF ( Table 2 ). The biggest difference was in miR-146b-5p, which was expressed 6.5-fold higher in VHD-RA-AF than in VHD-RA-SR based on array analysis and 4.2-fold when measured by qRT-PCR ( Table 2 ). The well-studied profibrotic miR-21 was also more highly expressed in AF tissues [by 3.4-fold based on array data and 4.2-fold from qRT-PCR (Table 2) ] along with its antisense miRNAs, miR-21* (2.3-fold higher in AF). Members of the miR-133 and miR-30 families were prominent among the miRNAs that showed lower expression in VHD-RA-AF than VHD-RA-SR (Tables 2 and 3) . Expression of miR-133a and miR-133b were reduced by ϳ50% in the AF group compared with the SR group, from array data or qRT-PCR (Tables 2 and 3) .
Despite the clear differences in miRNA expression profile in RA tissue, there were no differences in miRNA expressions in LA tissue from VHD patients with chronic AF compared with samples from patients who remained in sinus rhythm (VHD-LA-AF cf. VHD-LA-SR) that satisfied the statistical criteria (FDR Ͻ 0.05, FC Ͼ 1.5). Thus, we were unable to detect any AF-associated miRNA expression changes in LA tissue.
miRNA expression changes associated with VHD in LA and RA tissue. Our studies had demonstrated AF-related changes in miRNA expression profile only in RA, with no detectable differences being observed between profiles in VHD-LA-SR and VHD-LA-AF. We next examined the influence of VHD on miRNA expression profiles in LA samples from VHD patients by comparing these with LA tissue from healthy controls (VHD-LA; 11 samples, including SR and AF subgroups vs. healthy-LA, 5 samples). A total of 53 miRNAs showed an expression profile that was significantly different between VHD-LA and healthy-LA (FDR Ͻ0.05, FC Ͼ 1.5). Of these, 12 miRNAs were more highly expressed in VHD-LA compared with healthy-LA and 41 were expressed at lower level miRNAs that were differentially expressed between VHD-LA and VHD-RA were defined by fold change Ͼ1.5, false discovery rate Ͻ0.05, P Ͻ 0.01. miRNAs described as 'up' are higher in LA than in RA, whereas 'down' means expression is higher in the RA group.
( Table 4 ). We also compared miRNA profiles in VHD-RA with CABG-RA. Based on array data, only five miRNAs were differentially expressed between these two groups, with four being more highly expressed in VHD-RA than in CABG-RA and one miRNA being expressed at a lower level (FDR Ͻ0.05, FC Ͼ 1.5; Table 4 ). The miRNAs that were more highly expressed in VHD-RA than in CABG-RA included miR-21, which, as shown above, was further heightened in the AF subgroup relative to the SR subgroup of RA tissue (Fig. 1,  Tables 2 and 3 ). Only miR-490-3p showed similar expression changes with VHD in both LA and RA, where VHD was associated with reduced expression in both. miR-490-3p also showed lower expression with AF in the VHD-RA group (Tables 2-5) .
miRNA expression profiles in VHD RA and LA. As shown above, VHD caused different changes in miRNA expression in LA and RA. To identify miRNA expression differences between LA and RA from VHD patients, we next compared miRNA expression patterns in VHD-LA and VHD-RA. Thirteen miRNAs were more highly expressed in VHD-LA than in VHD-RA, and 26 were more highly expressed in VHD-RA (FDR Ͻ0.05, FC Ͼ1.5; Fig. 1B , Table 5 ). The chamber specificity of miR-10b expression is depicted in Fig. 2 , where expression levels in individual patients are shown. In Fig. 2A , expression levels in individual patients in relation to LA or RA origin, as well as AF/SR status. In Fig. 2B , expression of miR-10b is shown in LA and RA of the same patient. For each patient, miR-10b expression was higher in LA than in RA.
DISCUSSION
Using array technology, we investigated miRNA expression profiles in atrial appendage tissue from a number of patient groups, with a view to identifying changes in miRNA expression associated with VHD, and in particular with the development of AF on a background of VHD. The availability of both LA and RA appendage tissue provided an opportunity to examine the effects of disease on both of these tissues separately. Our data identified a number of miRNAs whose expressions were different in LA and RA. Furthermore, we showed that miRNA expression patterns in LA and RA are influenced differently by VHD and by chronic AF. Previously confirmed cardiac targets and possible functional significance of some of the miRNAs identified in our studies are described in Table 6 .
We found that the development of AF in VHD patients was associated with measurable changes in miRNA expression in RA but not in LA (Fig. 1A, Table 3 ). A recent study investigating miRNA expression in VHD patients in relation to AF also demonstrated changes in RA, many of which were also identified in the current study. However, this study did not investigate changes in LA tissue, and so a comparison with RA was not possible (36) . The lack of detectable difference between VHD-LA-AF and VHD-LA-SR in terms of miRNA expression profile may be partially due to tissue availability. LA appendage tissue is removed only from the most dilated atria, and therefore the VHD-LA group derives from the most severely affected patients. In contrast, RA appendage is re- 
IKK␣, inhibitor of nuclear factor B kinase (␣-subunit); PTEN, phosphate and tensin homolog (a PIP3 phosphatase); HCN2&4, hyperpolarization and cyclic nucleotide activated K ϩ channels involved in pacemaker function; HERG, human ether-a-go-go, a repolarising K ϩ channel (IKR); CTGF, connective tissue growth factor; TIAM1, a RAC GEF (guanylnucleotide exchange factor); mTOR, mammalian target of rapamycin, a growth-promoting protein.
moved from all patients undergoing valve surgery. This suggests the possibility that miRNA expression differences in the AF vs. SR groups are partly a reflection of the severity of the disease. On this basis, it is possible that miRNA expression changes in LA are already maximal at the time of surgery, regardless of AF status. We also found differences in miRNA expression between VHD-LA and VHD-RA. miR-10b was expressed preferentially in LA, whereas miR-100 was higher in RA (Figs. 1B and 2, Tables 2 and 5 ). miR-100 has previously been studied in relation to heart disease (29), whereas miR-10b has been primarily studied in relation to cancer progression (31), but our data suggest a role in pathology in the LA.
The miRNAs that were differentially expressed in VHD-RA-AF vs. VHD-RA-SR included profibrotic miRNAs [miR-21 (12) and miR-377 (34) ] that might be expected to contribute to AF by promoting fibrosis, an established AF substrate (3, 9) (Tables 2, 3, 5) . miR-133 and miR-30 family members showed lower expression in the AF group. Both the miR-133 and miR-30 families regulate connective tissue growth factor expression and thereby contribute to ventricular remodeling in heart failure (6) . In addition, miR-133 family members might directly influence arrhythmia outcomes by direct targeting of critical ion channels, including hyperpolarization and cyclic nucleotide regulated channel (HCN2&4) pacemaker K ϩ channels and the human ether-a-go-go (HERG, I kr ) repolarizing K ϩ channel (2, 5, 6, 20) , both of which have been implicated in the pathogenesis of AF (7, 13, 16, 28, 37) (Table 3) . miR-133a and miR-133b are muscle-specific miRNAs, and altered expression levels are associated with hypertrophy, fibrosis, and arrhythmia (5, 14, 20) . miR-133a and miR-133b are localized on chromosome 18, along with miR-1 family members, and the expression of these miRNAs is regulated by muscle-specific transcription factors including myocytes enhancer factor 2, serum response factor, and myocardin (32) . Thus, our data suggest transcriptional repression of this locus in RA of VHD patients with chronic AF. In contrast, miR-30 family members are expressed from different locations on chromosomes 1, 6, and 8, some being intronic and some intragenic. The finding that several of these miRNAs are downregulated in tissue from patients with AF suggests a co-coordinated repression of miR-30 members under these disease conditions (Fig. 1A, Table 3 ). Changes in miRNA expression in RA observed in relation to the VHD or AF share some similarities with changes reported previously in LV tissue of heart failure patients (6, 18, 22) .
VHD was associated with more pronounced changes in miRNA expression in LA than in RA (Table 4 ). This most likely reflects the primary role of LA in the genesis of the disease. Most of the miRNAs showing altered expression in VHD-LA have not previously been studied in heart, and a number of miRNAs currently recognized as promoting cardiac fibrosis were not included in this group (12, 33) . In RA samples, the established profibrotic miRNAs, miR-21, showed increased expression in VHD compared with CABG (Table 4) . The contribution of miR-21 to cardiac pathology has been well studied, especially in relation to ventricular remodeling in heart failure. miR-21 contributes to fibrosis by targeting Sprouty family members and phosphate and tensin homolog, which, in turn, repress growth signaling (12, 30) . The increased expression of miR-21 in VHD-RA therefore likely contributes to fibrosis associated with the progression of VHD. Interestingly, miR-146b-5p showed the largest increases in VHD-RA compared with CABG-RA. While this miRNA has not previously been investigated in relation to heart disease, potential targets of miR-146b-5p predicted by Targetscan include Sprouty family members that are confirmed targets of miR-21. These remain to be confirmed as real targets of miR-146b-5p in heart. miR-21 and miR-146b-5p have been reported to be regulated coordinately in inflammatory diseases (23) , and it is possible that they are also regulated in parallel in atrial disease. This possibility remains to be investigated. The only miRNA to be regulated similarly with VHD in LA and RA was miR-490-3p. This miRNA showed reduced expression in both LA and RA and was further decreased in the VHD-RA-AF group compared with VHD-RA-SR (Tables 2-5 ). This miRNA has not been extensively studied, but the data suggest a possible role in the pathology of VHD yet to be identified.
In summary, we have described miRNA expression changes associated with VHD and with AF in VHD patients. Some of the miRNAs identified as differentially expressed have been identified previously as promoting hypertrophy (miR-23a, miR-1, miR-133a), fibrosis (miR-133a, miR-30, miR-1, miR-21), or arrhythmia (miR-1, miR-133a) within the myocardium (6, 12) . In addition to these well-studied miRNAs, we identified changes in miRNAs not previously associated with cardiac pathology and some of these were altered specifically in LA. miRNA profiles in LA and RA respond differently to the challenge of VHD and the AF associated with VHD. 
